Collect whole blood in a purple top (EDTA) tube.
Refrigerate sample until shipment. Send the sample at room temperature with overnight delivery for receipt Monday through Friday within 24 hours of collection.
Whole blood can be refrigerated until shipment.
Heparinized specimens, severely hemolyzed specimens, frozen, clotted or possibly commingled specimens, blood in non-sterile or leaky containers, mislabeled or inappropriately labeled specimens.
Do not heat, freeze or centrifuge blood before shipment. Refrigerate sample until shipment.
Mon - Fri 9:00am to 4:00pm
Mowat-Wilson syndrome (MWS) is characterized by intellectual disability, severe speech impairment, Hirschsprung disease or severe constipation, genitourinary anomalies, congenital heart defects, agenesis or hypogenesis of the corpus callosum, eye defects (microphthalmia and Axenfeld anomaly), growth retardation, epilepsy, and microcephaly. Typical facial features include medially flared broad eyebrows, pointed chin, hypertelorism, uplifted ear lobes with a central depression and prominent columella.
All patients with a confirmed clinical diagnosis of MWS have mutations in the ZEB2 gene. ZEB2 is located on chromosome 2p22 and it encodes Smad-interacting protein-1 (SMADIP1). Missense, splice site, nonsense, and large deletions have been identified in the ZEB2 gene.
We offer DNA sequence analysis of the entire coding region. PCR amplification and sequencing is performed on all coding exons including splice junctions. The patient’s gene sequence is then compared to a reference sequence. Sequence variants are classified as mutations, variants of unknown significance or benign variants unrelated to disease. Variants of unknown significance may warrant further studies in the patient and other family members.
Sequence analysis of the ZEB2 gene detects point mutations in roughly 80% of patients with MWS. More than 50% of these mutations are present in exon 8 of the ZEB2 gene. The majority of cases are de novo.
Known mutation analysis is available to family members for mutations previously identified by sequence analysis.
Test results with interpretation will be mailed and/or faxed to the referring physician or send out lab following completion of the test. Additional reports will be provided as requested.
The clinical utility of the assay is to support a clinical diagnosis of the disease, facilitate genetic counseling, and assess the risk to other first degree relatives and to facilitate testing of at - risk family members.
Whole blood in EDTA purple top tubes is the preferred sample. High molecular weight genomic DNA, cheek epithelial cells, or other samples containing DNA may be acceptable. Contact the laboratory for specific instructions regarding such samples before sending the sample.